Breakthrough T1D RFA: Development of Continuous C-Peptide Monitoring Technologies for T1D
Breakthrough T1D has issued a new RFA – Development of Continuous C-Peptide Monitoring Technologies – to support the development of technologies for continuous C-peptide monitoring (CCPM), primarily through early-stage and preclinical studies, with potential application across all stages of T1D.
Proposals are invited for research to develop sensor platforms capable of detecting C-peptide at physiological concentrations with sufficient sensitivity, specificity, and stability for real-world, longitudinal use. While the primary focus is on continuous monitoring, proposals that enable high frequency or at-home testing will also be considered, provided they represent clear improvements over existing methods and support practical, scalable assessment of beta cell function.
Examples of research appropriate for this RFA include, but are not limited to:
- Early-stage development of sensor technologies capable of continuous or high-frequency C-peptide detection in biological fluids such as plasma or interstitial fluid.
- Preclinical development and validation of CCPM systems.
- Feasibility studies and early-stage clinical evaluation of CCPM technologies.
Depending on the context and maturity of the technology, CCPM platforms developed under this RFA may ultimately serve as:
- Improved tools for clinical care;
- Investigational tools to accelerate development of disease-modifying therapies; or
- Companion diagnostics to guide or monitor response to therapies such as immunotherapy or cell therapy.
Applications are invited from postdoctoral researchers holding a faculty position or equivalent at a college, university, medical school or other research facility based anywhere in the world. Applications may also be submitted by for-profit entities or industry/academic collaborations.
The maximum funding request for this RFA is $900,000 over three years. Applications are submitted under Breakthrough T1D’s Strategic Research Agreement (SRA) or Industry Discovery and Development Programme (IDDP) funding mechanisms. Non-profit organisations applying under the SRA may also include up to 10% for indirect costs.